Compare CBZ & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBZ | IDYA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | CBZ | IDYA |
|---|---|---|
| Price | $54.39 | $36.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $49.33 |
| AVG Volume (30 Days) | 502.5K | ★ 922.8K |
| Earning Date | 02-25-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | ★ $2,675,607,000.00 | $214,834,000.00 |
| Revenue This Year | $55.67 | $2,662.86 |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $32.02 | ★ N/A |
| Revenue Growth | 59.19 | ★ 5377.66 |
| 52 Week Low | $47.89 | $13.45 |
| 52 Week High | $90.13 | $39.28 |
| Indicator | CBZ | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 60.14 |
| Support Level | $52.46 | $32.59 |
| Resistance Level | $54.42 | $39.28 |
| Average True Range (ATR) | 1.59 | 1.43 |
| MACD | 0.19 | 0.17 |
| Stochastic Oscillator | 93.65 | 61.58 |
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the majority of its revenues from the Financial Services segment and geographically from the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.